ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
leverage factor · long-only model fund

Foundry Healthcare Book Leverage Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FBOHHYPOTHETICAL MODEL
Since ’99
−79%
Expense Ratio
0.45%
placeholder
Holdings
91
cap-weighted
Inception
Jun 2021
placeholder
Full Sharpe
-0.10
Ann. Return (LS)
-2.4%
Ann. Volatility
25.6%
Max Drawdown
-94.8%
Test Sharpe ’19–26
-0.36
Test FF5 α (ann.)
-3.6%
vs Fama-French 5
Test FF5 α t-stat
-0.50
not significant
Monthly turnover
10%
of the long leg, per rebalance
Cumulative return (LS)
-79%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.31
what this fund holds
Long leg ann. return
8.5%
buyable, long-only
Long-short Sharpe
-0.10
requires shorting
Bottom bucket ann. return
10.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

91 of 91 · 100.0% of book
TickerCompanySectorMarket capWeight
1UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
9.57%
2KRYS
KRYSTAL BIOTECH INCHealthcare$10.46B
4.40%
3APGE
APOGEE THERAPEUTICS INCHealthcare$10.10B
4.25%
4NUVL
NUVALENT INCHealthcare$9.79B
4.12%
5KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
4.01%
6PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
3.81%
7CRNX
CRINETICS PHARMACEUTICALS INCHealthcare$8.84B
3.72%
8PRAX
PRAXIS PRECISION MEDICINES INCHealthcare$8.77B
3.69%
9IMVT
IMMUNOVANT INCHealthcare$8.27B
3.48%
10PCVX
VAXCYTE INCHealthcare$8.12B
3.41%
11XENE
XENON PHARMACEUTICALS INCHealthcare$6.60B
2.78%
12CGON
CG ONCOLOGY INCHealthcare$6.34B
2.67%
13DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
2.43%
14ORKA
ORUKA THERAPEUTICS INCHealthcare$5.59B
2.35%
15VCYT
VERACYTE INCHealthcare$4.72B
1.99%
16MANE
VERADERMICS INCHealthcare$4.65B
1.96%
17EWTX
EDGEWISE THERAPEUTICS INCHealthcare$4.28B
1.80%
18TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
1.74%
19CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
1.62%
20RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.61%
21GPCR
STRUCTURE THERAPEUTICS INCHealthcare$3.45B
1.45%
22ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
1.36%
23IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
1.33%
24GRAL
GRAIL INCHealthcare$3.12B
1.31%
25MBX
MBX BIOSCIENCES INCHealthcare$2.99B
1.26%
26IRON
DISC MEDICINE INCHealthcare$2.91B
1.22%
27CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
1.17%
28TRVI
TREVI THERAPEUTICS INCHealthcare$2.71B
1.14%
29IMNM
IMMUNOME INCHealthcare$2.53B
1.06%
30SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
1.03%
31AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.99%
32PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
0.95%
33MLYS
MINERALYS THERAPEUTICS INCHealthcare$2.23B
0.94%
34SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.94%
35RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.86%
36AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.83%
37DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.82%
38TYRA
TYRA BIOSCIENCES INCHealthcare$1.91B
0.80%
39BCAX
BICARA THERAPEUTICS INCHealthcare$1.82B
0.77%
40STOK
STOKE THERAPEUTICS INCHealthcare$1.81B
0.76%
41MPLT
MAPLIGHT THERAPEUTICS INCHealthcare$1.72B
0.72%
42AVBP
ARRIVENT BIOPHARMA INCHealthcare$1.55B
0.65%
43BLFS
BIOLIFE SOLUTIONS INCHealthcare$1.42B
0.60%
44ABSI
ABSCI CORPHealthcare$1.29B
0.54%
45CRVS
CORVUS PHARMACEUTICALS INCHealthcare$1.25B
0.53%
46ORIC
ORIC PHARMACEUTICALS INCHealthcare$1.11B
0.47%
47CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
0.46%
48JBIO
JADE BIOSCIENCES INCHealthcare$1.03B
0.43%
49BIOA
BIOAGE LABS INCHealthcare$1.01B
0.43%
50OLMA
OLEMA PHARMACEUTICALS INCHealthcare$1.00B
0.42%
51JANX
JANUX THERAPEUTICS INCHealthcare$992M
0.42%
52ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.41%
53LBRX
LB PHARMACEUTICALS INCHealthcare$901M
0.38%
54SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.36%
55AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.35%
56DSGN
DESIGN THERAPEUTICS INCHealthcare$785M
0.33%
57BBNX
BETA BIONICS INCHealthcare$771M
0.32%
58MNPR
MONOPAR THERAPEUTICSHealthcare$744M
0.31%
59CLYM
CLIMB BIO INCHealthcare$727M
0.31%
60BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INCHealthcare$686M
0.29%
61SGP
SPYGLASS PHARMA INCHealthcare$661M
0.28%
62TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.26%
63NGNE
NEUROGENE INCHealthcare$590M
0.25%
64STTK
SHATTUCK LABS INCHealthcare$577M
0.24%
65FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.24%
66FLGT
FULGENT GENETICS INCHealthcare$573M
0.24%
67IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.23%
68RLMD
RELMADA THERAPEUTICS INCHealthcare$550M
0.23%
69CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
0.22%
70ZURA
ZURA BIO LTDHealthcare$518M
0.22%
71SGMT
SAGIMET BIOSCIENCES INCHealthcare$479M
0.20%
72PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.19%
73DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.19%
74BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.18%
75EVMN
EVOMMUNE INCHealthcare$437M
0.18%
76TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.18%
77CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.17%
78DMAC
DIAMEDICA THERAPEUTICS INCHealthcare$393M
0.17%
79UPB
UPSTREAM BIO INCHealthcare$382M
0.16%
80SLP
SIMULATIONS PLUS INCHealthcare$369M
0.16%
81RXST
RXSIGHT INCHealthcare$230M
0.10%
82UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.09%
83KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.09%
84TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.08%
85LENZ
LENZ THERAPEUTICS INCHealthcare$162M
0.07%
86PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.06%
87VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.05%
88AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.05%
89RLYB
RALLYBIO CORPHealthcare$87M
0.04%
90AGPU
AXE COMPUTE INCHealthcare$72M
0.03%
91IMA
IMAGENEBIO INCHealthcare$61M
0.03%

Full long-leg book as of July 2026 · cap-weighted · total market cap $237.65B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

91 classified
Value
Blend
Growth
Large
Mid
Small
7%3
32%8
27%9
8%11
15%17
4%4
6%30
1%6
1%3

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 79% toward Large, 56% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt79% → Large
SmallLarge
Value ↔ growth tilt56% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 91 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 91 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
2.1 (95% CI 1.3-2.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
19.9%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
2.06x
over
parametric
1.82x
within
cornish fisher
1.88x
within

The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.06 (fail) but Gaussian VaR gives 1.82 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1992
Entirely since publication
All 331 months of our record post-date the 1992 paper.
Sharpe -0.10-2.4% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
31%
8 of 26 3-year windows made money
Worst window
-1.27
Sharpe, January 2021 – December 2023
January 1999July 2026
Median Sharpe
-0.14
Dispersion
0.44
Best window
0.50

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.54.6%3.6%
3 yearsp.a.20.8%4.1%
5 yearsp.a.-1.1%-12.8%
10 yearsp.a.6.3%-7.0%
Since inceptionp.a.4.7%-5.5%
Calendar years
YearLong legLong-short
20267 mo15.6%3.2%
202523.5%-0.8%
202421.4%14.1%
2023-2.8%-8.0%
2022-26.3%-31.3%
2021-41.4%-55.3%
202055.6%32.8%
201920.2%-4.2%
2018-3.2%-2.1%
201750.9%21.4%
2016-28.0%-20.8%
2015-2.9%-3.7%
201429.8%-0.6%
201316.4%-25.2%
201217.3%-7.5%
201133.1%25.5%
20105.5%-7.4%
20099.6%-20.1%
2008-28.1%11.7%
200715.7%3.3%
20061.6%-7.2%
200513.7%-4.8%
2004-10.5%-13.9%
200357.4%28.9%
2002-43.9%-29.6%
2001-16.5%-6.0%
20000.6%-40.1%
199948.5%94.0%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FBOH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-06-18 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$237.65B

Methodology

The Foundry Healthcare Book Leverage Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Book Leverage signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.